Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders

Molecular Interventions

Volumn 5, Issue 4, 2005, Pages 211-215

  Pesu, Marko ^a   O'Shea, John ^a,d,e,f   Hennighausen, Lothar ^b   Silvennoinen, Olli ^c,g  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d American Association of Immunologists   (United States)

^e American College of Rheumatology   (United States)

^f American Society for Clinical Investigation   (United States)

^g UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR;

CELL COUNT; CELL PROLIFERATION; CELL TYPE; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; DNA SEQUENCE; ERYTHROPOIESIS; GENE IDENTIFICATION; GENE MUTATION; GENETIC CODE; HETEROZYGOSITY LOSS; MISSENSE MUTATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN;

HUMANS; JANUS KINASE 2; MODELS, MOLECULAR; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 24144475028     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.5.4.4     Document Type: Review

References (39)

1. Dameshek, W. Some speculations on the myeloproliferative syndromes. Blood 6, 372-375 (1951).
2. Van Etten, R.A. and Shannon, K.M. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6, 547-552 (2004). An excellent brief review on myeloproliferative disorders.
3. Bazan, J.F. Haemopoietic receptors and helical cytokines. Immunol. Today. 11, 350-354 (1990).
4. Boulay, J.L., O'Shea, J.J., and Paul, W.E. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 19, 159-163 (2003).
5. Leonard, W.J. and O'Shea, J.J. Jaks and STATs: Biological implications. Annu. Rev. Immunol. 16, 293-322 (1998).
6. O'Shea, J.J., Gadina, M., and Schreiber, R.D. Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell 109 Suppl., S121-S131 (2002). This review, together with the one above, provides a comprehensive view on Jak-Stat pathway.
7. b-/- mice due to decreased survival of early erythroblasts. Blood 98, 3261-3273 (2001).
8. Cui, Y., Riedlinger, G., Miyoshi, K., Tang, W., Li, C., Deng, C.X., Robinson, G.W. and Hennighausen, L. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol. Cell Biol. 24, 8037-8047 (2004).
9. Darnell, J.E., Jr., Kerr, I.M., and Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421 (1994). An outstanding review of the discovery of the Jak-Stat pathway by pioneers in the field.
10. Pesu, M., Candotti, F., Husa, M., Hofmann, S.R., Notarangelo, L.D., and O'Shea, J.J. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol. Rev. 203, 127-142 (2005).
11. -/- mice have impaired hematopoiesis.
12. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., and Pfeffer, K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409 (1998).
13. Yamaoka, K., Saharinen, P., Pesu, M., Holt, V.E., 3rd, Silvennoinen, O., and O'Shea, J.J. The Janus kinases (Jaks). Genome Biol. 5, 253 (2004).
14. Boggon, T.J., Li, Y., Manley, P.W. and Eck, M.J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analogue. Blood 106, 996-1002 (2005).
15. Saharinen, P., Takaluoma, K., and Silvennoinen, O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell Biol. 20, 3387-3395 (2000). Together with the next three reports describes the important regulatory role of JAK pseudokinase domain.
16. Chen, M., Cheng, A., Candotti, F., Zhou, Y.J., Hymel, A., Fasth, A., Notarangelo, L.D. and O'Shea, J.J. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains. Mol. Cell Biol. 20 947-956 (2000).
17. Saharinen, P., Vihinen, M., and Silvennoinen, O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell. 14, 1448-1459 (2003).
18. Luo, H., Rose, P., Barber, D., Hanratty, W.P., Lee, S., Roberts, T.M., D'Andrea, A.D., and Dearolf, C.R. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell Biol. 17, 1562-1571 (1997).
19. Argetsinger, L.S., Kouadio, J.L., Steen, H., Stensballe, A., Jensen, O.N., and Carter-Su, C. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell Biol. 24, 4955-4967 (2004).
20. Luo, H., Hanratty, W.P., and Dearolf, C.R. An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects. EMBO J. 14, 1412-1420 (1995).
21. Lindauer, K., Loerting, T., Liedl, K.R., and Kroemer, R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxyterminal domains reveals a mechanism for autoregulation. Protein Eng. 14, 27-37 (2001).
22. Giordanetto, F. and Kroemer, R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng. 15, 727-737 (2002).
23. Hofmann, S.R., Lam, A.Q., Frank, S., Zhou, Y.J., Ramos, H.L., Kanno, Y., Agnello, D., Youle, R.J. and O'Shea, J.J. Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited. Mol. Cell Biol. 24, 5039-5049 (2004).
24. Radtke, S., Haan, S., Jorissen, A. et al. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J. Biol. Chem. 280, 25760-25768 (2005).
25. Huang, L.J., Constantinescu, S.N., and Lodish, H.F. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol. Cell. 8, 1327-1338 (2001).
26. Zhou, Y.J., Chen, M., Cusack, N.A. et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: Structural implication for Janus kinases. Mol. Cell 8, 959-969 (2001).
27. Lacronique, V., Boureux, A., Valle, V.D. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 (1997).
28. Kralovics, R., Guan, Y., and Prchal, J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. 30, 229-236 (2002).
29. Bench, A.J., Nacheva, E.P., Hood, T.L. et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 19, 3902-3913 (2000).
30. Baxter, E.J., Scott, L.M., Campbell, P.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005). This and the following four papers identify V617F mutation in the JAK2 pseudokinase domain, and demonstrate its relevance in the pathogenesis of myeloproliferative disorders.
31. James, C., Ugo, V., Le Couedic, J.P. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 (2005).
32. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M., and Skoda, R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005).
33. Levine, R.L., Wadleigh, M., Cools, J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 (2005).
34. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B. and Zhao, Z.J. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 280, 22788-22792 (2005).
35. Dai, C., Chung, I.J., and Krantz, S.B. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp. Hematol. 33, 152-158 (2005).
36. Roder, S., Steimle, C., Meinhardt, G., and Pahl, H.L. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp. Hematol. 29, 694-702 (2001).
37. Changelian, P.S., Flanagan, M.E., Ball, D.J., Kent et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878 (2003).
38. O'Shea, J.J., Pesu, M., Borie, D.C., and Changelian, P.S. A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 3, 555-564 (2004).
39. Kaushansky, K. On the molecular origins of the chronic myeloproliferative disorders: It all makes sense. Blood 105, 4187-4190 (2005).